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Abstract: The etiology of human inflammatory bowel dis-
eases (IBDs) is believed to involve inappropriate host re-
sponses to the complex commensal microbial flora in the gut,
although an altered commensal flora is not completely ex-
cluded. A multifunctional cellular and secreted barrier sepa-
rates the microbial flora from host tissues. Altered function of
this barrier remains a major largely unexplored pathway to
IBD. Although there is evidence of barrier dysfunction in
IBD, it remains unclear whether this is a primary contributor
to disease or a consequence of mucosal inflammation. Recent
evidence from animal models demonstrating that genetic
defects restricted to the epithelium can initiate intestinal
inflammation in the presence of normal underlying immunity
has refocused attention on epithelial dysfunction in IBD. We
review the components of the secreted and cellular barrier,
their regulation, including interactions with underlying innate
and adaptive immunity, evidence from animal models of the
barrier’s role in preventing intestinal inflammation, and evi-
dence of barrier dysfunction in both Crohn’s disease and
ulcerative colitis.
(Inflamm Bowel Dis 2009;15:100–113)
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In all mucosal tissues a complex cellular and secreted barrierseparates the external environment from host tissues. The
physical, chemical, and microbial challenges to this barrier
are intensified in the intestinal tract due to the presence of
food and the symbiotic microbial community. Inflammatory
bowel diseases (IBDs) are complex polygenetic diseases
characterized by an unnecessary or exaggerated inflammatory
immune response to the microbial flora inhabiting the lumen
of the gut. Environmental factors are important in all human
IBD as the penetrance in monozygotic twins is less than 50%
in Crohn’s disease (CD) and less than 20% in ulcerative
colitis (UC)1 and these diseases require substantial life history
before they emerge. Much of IBD research has focused on the
nature of the inflammatory response and sought to identify
defects in leukocytes involved in innate and adaptive immu-
nity. However, recent data from animal models shows that
intestinal inflammation can be initiated by molecular defects
restricted to the epithelium in the presence of a normal
microbial flora and normal underlying innate and adaptive
immunity.2–4 Given the central role of the epithelium in
regulating inflammatory responses, the importance of the
intestinal barrier in limiting access of toxins and microbes to
underlying tissues, and the antimicrobial nature of the im-
mune responses in IBD, intestinal barrier dysfunction has
strong potential as a pathway to at least some subsets of IBD.
Unlike peptic ulcer disease and Helicobacter pylori, the
best evidence from human IBD does not support a specific
IBD-inducing bacterial infection.5 However, data do suggest
a role for chronic or recurrent microbial infection in the
ongoing pathogenesis of IBD. First, antibiotics are a useful
treatment in pouchitis (reviewed in Refs. 6,7). Second, there
is increased translocated bacteria in CD8–10 with a consequent
augmented humoral immune response.11 Third, in some mu-
rine models a colitogenic microbial flora has been described
that can induce colitis in mice with normal epithelium and
underlying immunity,12 and inflammation itself can favor
colonization of pathogenic aerotolerant bacteria.13
While altered barrier function occurs in IBD,14–16 a key
unanswered question confronting this aspect of IBD research
is whether dysfunction of the intestinal barrier in human IBD
is a primary contributor to inflammation or a consequence of
the action of inflammatory mediators. Nevertheless, regard-
less of whether altered barrier function makes a primary or
secondary contribution to pathology, restoring appropriate
barrier function remains a worthwhile therapeutic objective in
IBD. In this review we will describe the components of the
intestinal barrier, examine in vivo evidence that barrier dys-
function leads to intestinal inflammation, explore evidence of
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barrier dysfunction in human IBD, assess the potential of
therapeutic strategies to restore barrier function, and identify
the key research objectives for this aspect of IBD research.
COMPONENTS AND ROLES OF THE INTESTINAL
BARRIER
The intestinal barrier is composed of a thick secreted
mucus layer, a layer of epithelial cells and the underlying
nonepithelial mucosal cells, chiefly leukocytes with a range
of regulatory and effector functions (see Fig. 1). The elements
of the barrier change in different regions of the intestine and
can dynamically respond to environmental challenges. Too
often elements of this barrier are considered in isolation and
one of the major themes of this review will be that these
components are intrinsically linked in a complex physiology
and therefore need to be considered together in health and
disease. The secreted mucus barrier provides both a physical
and chemical barrier to microbes, as well as keeping the
mucosal surface well hydrated and providing lubrication al-
lowing the continuous flow of luminal contents. The epithe-
lial cells provide a structural barrier, manufacture most, but
not all, components of the secreted barrier, are sensors of the
external environment, and emit signals regulating underlying
innate and adaptive immunity. Nonepithelial mucosal cells,
although “underlying” the epithelium, can actually traverse
the epithelial barrier, manufacture some components of the
secreted barrier, and modulate epithelial cell function, includ-
ing modulation of the secreted barrier.
The Secreted Barrier
Misconception of the nature of the mucus barrier is
probably best represented by the drawings of researchers in
the field showing microbes in direct contact with the mucosal
epithelial cells. This misconception is fed by the artifactual
collapse and loss of the mucus layer during tissue handling,
particularly in preparation for histological examination (Mat-
suo et al17 took great care to preserve human intestinal mucus
and present striking images of intact, although collapsed,
mucus). Thus, many of the attempts to measure the mucus
layer underestimate mucus thickness. Imaging in live animals
and the use of electrodes demonstrate that the mucus layer in
the rodent colon is around 800 m thick, consisting of an
inner firmly adherent layer of around 100 m and an outer
more loosely adherent layer of around 700 m, demonstrated
diagrammatically in Figure 1.18 Thus, a bacterium residing in
the colonic lumen needs to traverse around 1000 bacterial cell
lengths of thick viscous mucus packed with antimicrobial
molecules to make contact with the epithelial cell surface.
The actual location of microbes in the intestine remains
controversial. In situ hybridization studies, which are the best
available methods of localizing microbes in tissue sections,
are dogged by the technical problems referred to above.
Using scanning electron microscopy Bollard et al19 showed
that bacteria were positioned exclusively outside the mucus
layer in the rat intestine when antibodies were used to stabi-
lize mucus. However, without stabilization prior to process-
ing, even with great care to preserve mucus, bacteria were
seen within the mucus, and even within crypts and in contact
with epithelial cells.19 Most in situ studies have failed to try
and preserve mucus or relied on Carnoy’s fixative to maintain
mucus, and consequently the conclusions of these studies are
likely to be erroneous. On best evidence at least the inner
mucus layer appears largely sterile,20,21 but whether bacteria
reside in large numbers within the outer mucus layer remains
unclear, as it is very easily dislodged on handling and lost
during tissue processing.
The major macromolecular component of intestinal
FIGURE 1. Diagrammatic representation of the mucosal bar-
rier in the colon of the mouse showing the thickness of the
secreted mucus barrier and the relationship between the lumi-
nal microbiota and the epithelium.
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mucus is the mucin glycoprotein synthesized by goblet cells
encoded by the MUC2 gene, which resides in a cluster of 4
mucin genes on chromosome 11p15.5.22,23 Each MUC2 sub-
unit protein is over 5000 amino acids in length and over 70%
carbohydrate by weight. These subunits dimerize in the en-
doplasmic reticulum and then following glycosylation in the
Golgi undergo further homo-oligomerization to form com-
plex multimers that are primarily responsible for the viscous
properties of mucus.24–26 While mucins provide the matrix, it
is vitally important to recognize that mucus is a complex
mixture of mucins and other compounds secreted by the
epithelium, including phospholipids. Although some specific
domains and specific carbohydrates on other mucins have
been shown to have direct antimicrobial activity27,28 or to
bind antimicrobial molecules such as histatins and
statherin,28,29 this has not yet been demonstrated for MUC2.
However, the intestine secretes many other compounds into
mucus that are involved in barrier function, and some of these
molecules and their functions are listed in Table 1.
A key function of mucus is to retain a high concentra-
tion of antimicrobial molecules in the environment close to
the epithelium. It is often not appreciated that the efficacy of
these compounds is dependent on their retention in mucus.
For example, consider how ineffective defensins in the small
intestine would be if they were merely secreted into the large
volume and continuous flow of material within the lumen.
The defensins are secreted in granules produced by Paneth
cells into small intestinal crypts that are completely filled
with mucus. In fact, while most of this mucus is derived from
goblet cells, Paneth cells also synthesize MUC2, which is
packaged into the granules with the defensins and other
antimicrobial peptides ensuring that they are co-secreted
(McGuckin, unpubl.). It is tempting to speculate that reten-
tion of the polycationic defensins in mucus is enhanced by
electrostatic interaction with the polyanionic mucin mole-
cules (sulfated and sialylated mucin oligosaccharides are
negatively charged). There is much to learn of the complex
interactions between components of mucus and how they
operate in barrier function in health and disease.
The Cellular Barrier
In addition to producing the major elements of the
secreted barrier, underlying epithelial cells form a physical
barrier limiting access of microbes and toxins to host tissues.
Intestinal epithelial cells form a polarized layer of cells
tightly linked via intercellular tight junctions and are covered
with a complex apical glycocalyx that includes a family of
large cell surface mucin glycoproteins. The epithelial cells
TABLE 1. Molecular Elements of the Intestinal Mucus Barrier Relevant to Barrier Function
Component Source Regulation Function
Mucin (MUC2) Goblet cells, Paneth cells Constitutive. 1 TLR ligands,
inflammatory cytokines,
growth factors, lipid
mediators, hormones,
neural stimulus
Major macromolecular component of hydrophilic
hydrated mucus: physical barrier, hydration,
lubrication, retention of antimicrobial
molecules
Immunoglobulins (sIgA,
IgG, IgM) Secretory
component (SC) and
FcRn
B lymphocytes, epithelial
cells (SC and FcRn)
Constitutive. Regulated by
antigen presenting cells,
helper T cells and
epithelial cells.
Antimicrobial: opsonization of microbes,
blocking microbial penetration of mucus SC
and FcRn facilitate transport across epithelium.
Glycosylated SC protects Fc region of IgA
dimer in external environment.
Trefoil peptides (ITF/
TFF3)
Goblet cells Constitutive. Regulation not
well understood.
Co-secreted with MUC2, possible modulator of
mucin polymerization, stimulator of wound
repair.
Antimicrobial peptides
(defensins,
cathelicidins,
lysozyme, PLAP2)
Paneth cells, enterocytes Constitutive. TLR and NOD
ligands, cholinergic stimuli.
Peptides with direct antimicrobial activity.
Phospholipids Enterocytes Not known Hydrophobic element of mucus probably
interdispersed in striated layers with hydrated
mucus: lubrication and barrier function
Lectins (RegIII,
collectins)
Paneth cells, enterocytes Constitutive and regulated by
TLR ligands (e.g,. RegIII
expression is lost in
MyD88-/- mice)
Direct antimicrobial activity.
Antimicrobial protease
inhibitors (SLPI,
elafin)
Epithelial cells,
leukocytes
Constitutive and increased by
inflammation.
Some direct antimicrobial activity.
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are equipped to phagocytose bacteria, sequester and neutral-
ize toxins, detect prokaryocytic-associated molecular patterns
(PAMPs), and respond by bolstering secreted defense, initi-
ating wound repair and activating underlying innate and
adaptive immunity.30 Epithelial crosstalk with underlying
immunity is a 2-way communication that is critical in the
regulation of the nature of the response to microbial and toxic
stimuli.31 For example, it has recently emerged that epithelial
molecules regulate class-switching by B cells in the lamina
propria.32 Some leukocytes are physically integrated within
the epithelium as dendritic cells extend processes between
adjacent epithelial cells,31,33 and some specialized T cells and
NK cells reside between epithelial cells.34
Interaction of the Intestinal Barrier with Commensal
and Pathogenic Microbes
The intestinal lumen contains a complex community of
microbes35 generally living in a commensal symbiotic rela-
tionship with the host, providing nutrients and maturing the
immune system (see reviews 36,37). The intestinal secreted
and cellular barrier limits contact between these microbes and
underlying host tissues while supporting the growth of the
commensal flora. As discussed above, in situ morphological
localization studies that preserve the mucus layer show that
commensal microbes largely reside on and outside the surface
of mucus, positioning them well away from the surface of
mucosal epithelial cells.20 A critical exception to this physical
separation occurs in the dome epithelium above Peyer’s
patches in the small intestine. This epithelium lacks goblet
cells and therefore lacks a secreted mucus barrier and has
altered expression of cell surface glycoproteins.38,39 This
allows microbes to come in contact with M-cells that phago-
cytose and transport the microbes to underlying dendritic
cells for presentation of antigen in mesenteric lymph nodes.40
The seminal work of Andrew Macpherson demonstrates that
the nature of the ensuing immune response to the commensal
microbial flora sampled in this way is noninflammatory and
dominated by production of sIgA.41–43 sIgA is secreted into
mucus and helps prevent penetration of the mucus barrier by
commensal organisms expressing the target surface antigens.
The strategies used by intestinal pathogens to infect
intestinal epithelium perhaps provide the best evidence to
date of how the functions of the secreted mucus barrier
prevent commensal organisms from penetrating epithelia.
Intestinal pathogens, almost by definition, have evolved
mechanisms to subvert or avoid the secreted mucus barrier.
They are virtually all motile, allowing them to move in
mucus, and many bind mucin carbohydrates and produce
enzymes that break down the mucin polymer network to
facilitate penetration of mucus.44–48 The protozoan parasite
Entamoeba histolytica cleaves MUC2 in a manner likely to
depolymerize the MUC2 complex, leading to loss of viscosity
and disintegration of mucus.49 In addition, many intestinal
pathogens have adhesins that allow them to dock onto the
epithelial surface. In contrast, there are other intestinal patho-
gens that avoid the barrier by exploiting the hole in mucus
over the dome epithelium and infect via M-cells.50–52 While
the dome epithelium seems a deficit in host defense, espe-
cially in the context of the life-threatening nature of gastro-
intestinal infections, one can conclude in an evolutionary
sense that it has proved more important for mammals to
maintain controlled immunity to the normal flora than to
completely block access to potential pathogens. In contrast to
the noninflammatory sIgA response mounted against com-
mensal flora, when pathogens cross the barrier and disrupt the
epithelium, an inflammatory response is generated more akin
to the chronic inflammatory response in IBD.41
Thus it is conceivable that IBD could ensue due to
either the presence of persistent “pathogenic” microbes, de-
fects in the intestinal barrier, inappropriate underlying im-
mune responses to “normal” sampling and presentation of
commensal antigens, or to failure of the inflammatory im-
mune response to downregulate once a pathogen is cleared.
None of these elements are mutually exclusive and a combi-
nation of these factors, both genetic and environmental, could
be involved in the development of IBD. The increased inci-
dence of IBD in the developed world in the early 20th
Century followed by the more recent increased incidence in
Asia coincides with fewer gastrointestinal infections and the
advent of treatment of those infections (e.g., with antibiotics)
implicating the exposure to these infections inversely with the
risk of developing IBD.53,54
Regulation of the Intestinal Barrier
Although most of the key elements of the mucus barrier
are secreted constitutively, both rates of production and se-
cretion are regulated in an autocrine fashion by epithelial
cells responding to PAMPs and other environmental stimuli,
and in response to paracrine stimulation by other epithelial
cells and lamina propria lymphocytes, and endocrine and
nervous stimuli (see Table 1). As an example, MUC2 tran-
scription is increased in response to inflammatory cyto-
kines,55–59 PAMPs,60–62 growth factors,63 lipid mediators64
and hormones,65,66 and secretion of the mucin by goblet cells
is increased by PAMPs, toxins, and nervous stimuli.56,58,67–69
Furthermore, it is emerging that the glycosylation of MUC2
can be modulated by inflammatory stimuli.70,71 Similarly,
production and release of defensins, lectins, and other Paneth
cell products are upregulated by bacterial products and in-
flammatory cytokines.72–77 Thus, the secreted barrier should
not be viewed as static or nonresponsive, but rather as an
integrated component of innate and adaptive immunity that
can be altered in terms of overall quantity and nature, and the
relative abundance of the key individual components. Psy-
chological stress can modulate barrier function and this may
at least partially explain the links between stress and IBD
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(reviewed in 78). In animal models experimental psycholog-
ical stress increases intestinal permeability, depletes goblet
cells and the mucus barrier and can lead to reactivation of
colitis.79,80
EVIDENCE THAT THE INTESTINAL BARRIER
PREVENTS INFLAMMATION
Secreted Barrier Defects
There are no intestinal in vitro culture systems that
replicate the complexity of the secreted mucus barrier (for a
discussion of this with respect to mucins and mucus, see Ref.
81). Furthermore, no in vitro systems can duplicate the com-
plexity of regulation of the cellular and secreted barrier by
underlying innate and adaptive immunity. Indeed, the lack of
secreted barriers needs to be carefully considered when in-
terpreting studies of barrier function conducted in vitro. Con-
sequently, the most physiologically relevant data regarding
the importance of the intestinal barrier comes from animal
model systems of infection and inflammation (some of the
most informative models are listed in Table 2).
Somewhat surprisingly, mice with reduced numbers of
intestinal secretory lineage cells (both goblet cells and Paneth
cells) have not been reported to develop spontaneous inflam-
mation.82,83 However, both Gfi/ mice, which have a partial
depletion, and particularly Math1/ mice, which have a
much greater depletion of secretory cells, die fairly early in
life due to other complications. Intestinal specific knockout of
Math1/ has been achieved with complete loss of secretory
lineage cells in 75%–90% of crypt/villus axes in the small
intestine and crypts in the large intestine,84 and these mice
survive and do not develop spontaneous colitis. Furthermore,
when 60% of goblet cells were depleted by expression of
the diphtheria toxin under the ITF promoter, mice were
unexpectedly more resistant to dextran sodium sulfate (DSS)-
induced colitis.85 These data indicate not only that simple
reduction of the total number of goblet cells is insufficient to
predispose to colitis, but also suggest that the predisposition
to DSS-colitis resides in the goblet cells themselves because
reducing the number of goblet cells reduced the predisposi-
tion. However, demonstrating that intestinal mucus prevents
colitis, knockout of the intestinal mucin gene, Muc2, leads to
spontaneous colitis at least on some mouse backgrounds.3
(Although the original report of these mice claimed that
intestinal tumors evolved in the absence of inflammation, the
mice were reported to have increased crypt length and pro-
liferation, which are well accepted signs of colitis in mice.86)
Even though the classical goblet cell thecae are lost in
Muc2/ mice, the goblet cells are present and produce other
secretions and partially compensate by neo-expression of the
gastric mucin, Muc6, in the intestine.86 The development of
colitis is not surprising given that Muc2 is the molecule
responsible for the viscous properties of mucus and its loss is
likely to lead to dispersion of all other epithelial secretions, so
bringing the luminal flora in contact with the epithelium and
diluting the efficacy of antimicrobial molecules such as de-
fensins and immunoglobulins.
Although the Muc2/ demonstrates the importance of
the mucin, and goblet cells are reduced in number and size in
UC, there are no humans with total loss of MUC2/goblet cell
thecae (although small intestinal goblet cells are sometimes
near absent in rare individuals with autoimmune enteritis due
to antigoblet-cell antibodies87). Using random mutagenesis
we have generated and characterized 2 strains of mice with
single missense mutations in Muc2 that develop a UC-like
colitis phenotype with mild distal colonic inflammation, in-
creased intestinal permeability, and increased production of
IL-1, TNF-, IFN-, and IL-13.4 Both of these single nu-
cleotide polymorphism (SNP) mutations cause aberrant as-
sembly of the mucin complex leading to endoplasmic retic-
ulum (ER) stress in goblet cells and Paneth cells, premature
apoptosis and reduced mucin secretion, all of which are found
in UC (see below). We believe that both ER stress and
depletion of the mucus barrier contribute to inflammation in
these models, which are the only animal models of sponta-
neous colitis due to single point mutations in any gene.
Environmental ER stressors could duplicate this phenotype
by increasing mucin misfolding and reducing mucin produc-
tion. They may also give rise to inflammatory activation via
initiation of the unfolded protein response, which can directly
promote inflammation,88,89 including via activating NF-B in
ER-stressed cells.90–93 These models resemble UC and dem-
onstrate that underlying defects in MUC2, the molecular
machinery of ER stress, or the unfolded protein response
could collectively or individually lead to prolonged inflam-
mation once an infection has been cleared.
Changes in mucin glycosylation can also alter barrier
function and contribute to colitis susceptibility. Mice lacking
a Golgi resident enzyme (core 3 beta1,3-N-acetylglucosami-
nyltransferase) responsible for production of mucin Core 3
O-glycans show consequent changes in glycosylation of in-
testinal Muc2 with increased expression of the Tn oligosac-
charide.94 In addition to the glycosylation changes, these
mice show decreased intestinal production of Muc2, in-
creased intestinal permeability, and increased susceptibility
to induced colitis. Furthermore, we have recently demon-
strated increased susceptibility to infection and DSS-induced
colitis in mice lacking a sulfate transporter which causes
hyposulfatemia and reduced sulfation of intestinal mucins95
(P. Dawson, unpubl.).
Trefoil peptides (TFFs) are small protease resistant
proteins that are co-secreted with mucins into mucus.96 In-
testinal trefoil peptide (ITF, TFF3) is co-produced and se-
creted with MUC2 by intestinal goblet cells,97 whereas in the
respiratory tract TFF3 is co-secreted with both MUC5B and
MUC5AC.97,98 The viscosity of mucin solutions increases
following addition of recombinant TFFs, suggesting that
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TABLE 2. Animal Models Demonstrating the Importance of Intestinal Barrier Function
Animal Model Description
Susceptibility
to Intestinal
Infection
Severity of
Induced
Colitis
Spontaneous
Colitis References
Depletion of Secretory Lineage Cells
Math1-/- Math1 is a transcription factor involved in
differentiation of the intestinal secretory lineage.
Knockouts and intestinal specific knockouts under a
villin promoter produce no secretory lineage cells but
die very early in life, apparently without colitis.
Intestinal specific knockout under the Fabpl promoter
results in a mosaic loss in secretory cells in 75-90%
of crypts in the distal small intestine and the colon,
and mice survive without colitis.
NT NT No (82, 84)
Gfi1-/- Gfi1 is a transcription factor involved in
differentiation of the intestinal secretory lineage.
Knockouts produce few secretory lineage cells (more
than Math1) and survive longer but still die early,
apparently without colitis.
NT NT No (83)
mITF/DT-A 60% depletion of colonic goblet cells by expression
of diphtheria toxin under control of the ITF (TFF3)
promoter. Actually more resistant to DSS-induced
colitis.
NT Decreased No (85)
Alterations in Intestinal Secreted Mucins
Muc2-/- Muc2 is the main secreted intestinal mucin and
knockouts lack goblet cell thecae but continue to
make other goblet cell secretions like ITF. Knockouts
develop spontaneous colitis (at least on some mouse
backgrounds) and show increased susceptibility to
DSS-induced colitis. Some compensatory production
of gastric mucin Muc6.
NT Increased Yes (3, 86)
Winnie, Eeyore Mice with single missense mutations in Muc2 leading
to aberrant mucin assembly, ER stress and reduced
mucin secretion. Develop spontaneous distal colitis
with increased intestinal permeability and increased
production of both Th1 and Th2 cytokines. Extremely
sensitive to low doses of DSS.
Increased Increased Yes (4)
C3GnT
transferase-/-
Knockout of transferase results in loss of core 3-
derived O-glycans on Muc2. Decreased mucin
synthesis, increased intestinal permeability and
increased susceptibility to DSS-induced colitis.
NT Yes No (94)
Alterations in Intestinal Cell Surface Mucins
Muc1-/- Cell surface mucin upregulated during intestinal
infection. Knockout mice are more susceptible to
infection with gastrointestinal pathogens.
Increased NT No (113, 114)
Muc13-/- Cell surface mucin highly expressed in large and
small intestine. Knockout mice are more susceptible
to DSS-induced colitis and develop more rapid C.
rodentium infection.
Increased Increased No (McGuckin
unpubl. obs.)
Alterations in Intestinal Trefoil Factor (TFF3)
TFF3-/- ITF is the major intestinal trefoil. Knockout mice do
not develop spontaneous colitis but are more
susceptible to DSS colitis and radio/chemotherapy
induced mucositis.
NT Increased No (105, 169)
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TFF-mucin interactions could modulate the rheological prop-
erties of the mucus gel.99 Quite separate from this putative
role as structural components of the gel, recombinant TFFs at
high concentrations have motogenic, proliferative, and anti-
apoptotic effects on cells cultured in vitro and are therefore
thought to be important in mucosal wound repair.100–104 TFF3
knockout mice do not develop spontaneous colitis but show
enhanced susceptibility to DSS-induced colitis,105 which
could be mediated through poorer mucus quality and/or in-
adequate wound repair.
A relatively large array of antimicrobial molecules are
produced by intestinal epithelia, including defensins, lectins,
histatins, statherins, enzymes, and protease inhibitors. The
antimicrobial activity of these molecules has been established
in vitro, and for some molecules there are in vivo data
supporting functional importance in limiting penetration of
the mucus barrier by the normal flora and limiting infection
by pathogens. However, there are no data demonstrating that
loss of individual antimicrobial components leads to sponta-
neous intestinal inflammation. Because there are no defensin
(cryptidin)-deficient mice strains described it is difficult to
ascertain the relative importance of these molecules. How-
ever, mice transgenic for human defensin-5 show greater
resistance to Salmonella infection.106 Conversely, MMP7
knockout mice that have aberrant cryptidin processing are
more susceptible to infection,107 showing that these mole-
cules can limit pathogens in vivo, but they do not develop
spontaneous inflammation.107 Furthermore, CARD15/Nod2
knockout mice have decreased cryptidin production, with
increased susceptibility to intracellular infection by oral but
TABLE 2. (Continued)
Animal Model Description
Susceptibility
to Intestinal
Infection
Severity of
Induced
Colitis
Spontaneous
Colitis References
Alterations in Antimicrobial Peptides and Lectins
RegIII-/- Mice deficient in MyD88 do not express RegIII in
the ileum and are more susceptible to ileal infection
with Listeria. This susceptibility is also seen in
mice treated with anti-RegIII antibodies.
Increased NT No (170)
Defensin
transgenic
Mice overexpressing human defensin-5 show
increased resistance to Salmonella infection.
Decreased NT No (106)
MMP7-/- Defective cryptidin (murine defensin) processing due
to loss of metalloproteinase MMP7; other features
of any phenotype could be attributable to non-
defensin related function of MMP7.
Increased NT No (107)
SLPI-/- Mice lack the secretory leucocyte protease inhibitor
(SLPI). More susceptible to respiratory infection
but not tested specifically in intestinal infection or
colitis but no reported spontaneous colitis.
NT NT No (171)
Alterations in Mucosal Immunoglobulins
Rag1/2-/- Mice cannot recombine the B-cell receptor and also
the T-cell receptor – combined B- and T-cell
deficiency.
Increased Decreased No (109, 172)
microMT Mice have specific B-cell deficiency Increased NT No (108, 109)
pIgR-/- Mice lack the receptor that transports IgA across the
epithelium forming secretory IgA (sIgA).
Compensation by increased IgG is possible.
Increased No No (111)
FcRn-/- Mice lack the receptor that transports IgG across the
epithelium. Compensation by increased sIgA is
possible.
Increased No No (112)
Alterations in Epithelial Cell Barrier Function / Undetermined
SAMP1/YitFc Undefined spontaneously generated genetic model
that develops spontaneous ileitis. Bone marrow
transplantation experiments show that the genetic
deficit resides in the epithelial compartment and
that secretory cell hyperplasia, production of relm-
 and increased intestinal permeability precede
inflammation.
NT NT Yes (122, 125, 126,
173)
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not intraperitoneal Listeria monocytogenes, but again do not
develop spontaneous inflammation.76 Given the substantial
number of different antimicrobial molecules in mucus it is
unlikely that loss of, or aberrant function of, any individual
molecule would impair innate defense sufficiently to lead to
spontaneous inflammation from the commensal microbes.
However, defects in molecules regulating their overall pro-
duction, processing, or secretion may be more likely to com-
promise innate defense and lead to inflammation.
The adaptive immune system makes a substantial in-
vestment in producing mucosal immunoglobulin, with sIgA
constituting the greatest proportion of immunoglobulin syn-
thesis. Despite the importance of secreted immunoglobulins
in eliminating pathogens and keeping commensal flora away
from the epithelial cells, there are no data that demonstrate
that deficiencies in immunoglobulin production lead to spon-
taneous intestinal inflammation. Mice that cannot recombine
the B-cell receptor and mice specifically lacking B-cells are
more susceptible to infection with intestinal pathogens but do
not develop spontaneous colitis.108,109 Similarly, mice lacking
secretory component (pIgR) or FcRn that are responsible for
transporting IgA and IgG, respectively, across the mucosa are
more susceptible to infection but do not develop spontaneous
intestinal inflammation.108,110–112
Cellular Barrier Defects
Emerging evidence suggests that the cell surface mu-
cins present in the glycocalyx of all mucosal epithelial cells
may be important determinants of infection. We have re-
cently demonstrated that deficiency of the Muc1 mucin ren-
ders mice more susceptible to infection by some gastrointes-
tinal pathogens.113,114 In the case of Campylobacter jejuni
infection, Muc1 appears to not only impede penetration of the
mucosal barrier by the pathogen but to modulate the epithelial
cell response to a bacterial genotoxin.113 In the case of H.
pylori infection Muc1 knockout mice develop more severe
inflammation than wildtype mice, demonstrating that cell
surface mucins can modulate the inflammatory response to
chronic infection.114 We have recently generated mice lack-
ing Muc13, which is highly and constitutively expressed in
the small and large intestine. Although these mice do not
develop overt spontaneous inflammation they appear more
susceptible to DSS-induced colitis and Citrobacter rodentium
infection (McGuckin, unpubl.).
Although increased permeability is a feature of IBD,
where it has been demonstrated especially in active ileal CD,
and appears in many animal models of intestinal inflamma-
tion, there are few compelling data that increased permeabil-
ity alone results in chronic intestinal inflammation. Mice
transgenic for a dominant negative N-cadherin develop spon-
taneous ileitis but have additional major disturbances in cell
proliferation, migration, and apoptosis that are likely to con-
tribute to their phenotype.115 The inflammatory cytokines
IL-1, TNF-, IFN-, and IL-13 increase intestinal perme-
ability largely by inducing the myosin light chain kinase
(MLCK), which in turn destabilizes tight junctions.116–121
Thus, once inflammation is established altered epithelial per-
meability ensues and contributes to the severity of pathology
and the ability to resolve inflammation and repair wounds.
SAMP1/YitFc mice develop spontaneous ileitis that
shows many features similar to Crohn’s ileitis and are likely
to have multi-allelic contributions to phenotype.122–124 De-
spite the observation that T cells from these mice can induce
ileitis in lymphopenic recipients,122 it has recently emerged
that the genetic defects in these mice act via the epithelial
cells rather than leukocytes.125 In these mice, hypertrophy of
secretory lineage cells and increased intestinal permeability
predate inflammation,125,126 which suggests that a barrier
function defect may underlie this phenotype. Further dissec-
tion of the mechanism of pathology in mice like SAMP1/
YitFc with multi-allelic contributions is likely to increase
insights as to the importance of barrier function in preventing
intestinal inflammation.
BARRIER FUNCTION IN IBD
Perturbations in barrier function in human IBD include
reduction in barrier and antimicrobial secretions, reduced
numbers of secretory cells, increased permeability, disabled
tight junctions, through to substantial reduction, and even
complete loss of the epithelium where ulceration occurs.
While many may argue that most of these are consequences
rather than causes of inflammation, the data from animal
models as described above suggest that barrier dysfunction
could plausibly be a primary defect in some subsets of IBD.
Even if this is not the case, these features will exacerbate
inflammation and complicate resolution of lesions. The mu-
cus layer in IBD appears more highly populated with bacte-
ria, particularly in areas where there is minimal or less severe
inflammation127 (Florin, unpubl.). These studies are beset by
technical problems discussed earlier and uncontrolled envi-
ronmental effects that make interpretation difficult.128 In the
following sections we discuss altered barrier function in CD
and UC separately, but it is likely that there are both sub-
stantial overlaps between these diseases and substantial vari-
ation within each of these broad disease classifications in
barrier function phenotypes.
Crohn’s Disease
In classical ileal CD the conventional dogma is that
there is goblet cell hypertrophy and increased, rather than
decreased, mucus formation,129,130 which suggests that a de-
ficiency in secreted mucus does not underlie this disorder.
However, in recent years attention has been focused on
Paneth cells in CD because of data indicating decreased
defensin production,131–134 expression of NOD2 within Pan-
eth cells,135,136 and demonstration that the NOD2 microbial
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ligand, MDP, increases transcription of defensin genes.77
Most of the data on defensins are derived from polymerase
chain reaction (PCR) amplification of RNA from tissue bi-
opsies from patients and controls. The relative abundance of
epithelium decreases during intestinal inflammation. There-
fore, studies based on whole tissue RNA are fraught with the
potential to wrongly attribute a decrease in the relative abun-
dance of epithelial specific RNA to decreased production of
molecules per remaining epithelial cell rather than to de-
creases in the relative abundance of epithelial cells.
In this regard, we have recently conducted a study in
which we demonstrate increased rather than decreased defen-
sin expression in noninflamed ileal CD.137 In inflamed tissue
the decreased defensin mRNA expression was paralleled by
decreased expression of another epithelial-specific gene, vil-
lin.137 Furthermore, by immunohistochemistry we showed
that the residual Paneth cells in inflamed ileal CD tissue
express protein levels of human defensin-5 that appear sim-
ilar to Paneth cells from noninflamed CD tissue, regardless of
CARD15 (NOD2) genotype. Interestingly, despite the role of
MDP in stimulating defensin production via NOD2,77 defen-
sin expression was not related to NOD2 mutation status in our
study.137 Our conclusion is that these data do not yet support
a fundamental decrease in defensin production underlying
ileal CD. In colonic CD there is some evidence of decreased
antimicrobial activity in crude cationic protein preparations
extracted from biopsies when compared with UC and healthy
controls.138 The same group also reported that there was
decreased antimicrobial protease inhibitors SLPI and elafin in
inflamed CD compared with inflamed UC.139 Production of
all antimicrobial molecules in inflamed and noninflamed in-
testine from patients with accurately phenotyped ileal and
colonic CD needs to be assessed in thorough analyses that are
well controlled for numbers of epithelial and inflammatory
cells in the individual biopsies. These studies need to be
sufficiently powered to permit subanalysis for the major CD
subsets.
Using noninvasive techniques many, but not all,123
studies have demonstrated increased intestinal permeability
in CD.14,15,140-142 While the mechanism and cellular site of the
increased permeability measured in humans are not precisely
known, this is likely to be attributable to the actions of the
Th1 cytokines TNF- and IFN- that are characteristic of this
disease and known to increase permeability.143 Underlying
this increased permeability are reduced numbers of tight
junctions and reduced expression and relocation of claudin
isoforms involved in tight junctions in active CD.144 Bacterial
translocation is frequently reported in CD,8–10 suggesting that
the altered permeability to small molecules and disrupted
tight junctions is functionally significant. However, increased
bacterial translocation could be due to multiple factors in-
cluding impaired bacterial processing possibly associated
with CARD15 and ATG16L1 mutations,145–147 a more virulent
bacterial flora with increased epithelial adhesins,148 or in-
creased ligands for bacterial adhesins in CD.149 Evidence that
clinically unaffected family members of CD sufferers can
have increased intestinal permeability suggests that this could
be an early predisposing factor.150
Ulcerative Colitis
Unlike CD, UC is usually characterized by a reduction
in goblet cells, reduced size of goblet cell thecae, decreased
MUC2 production,151,152 decreased mucin sulfation,152–154
and a diminished mucus barrier. The mucus diarrhea often
seen clinically in UC may be indicative of poor mucus quality
leading to reduced retention at the mucosal surface. These
characteristics are usually dismissed as being a response to
inflammation, as similar changes in goblet cells can occur in
infectious colitis. However, these features are also observed,
albeit to a lesser degree, in unaffected proximal intestine of
patients with distal UC, suggesting that it could be an early
predisposing factor predating histological colitis. Not so well
known but equally relevant, vacuolization of the ER and
Golgi is observed in both inflamed and noninflamed secretory
cells in the intestines of UC but not CD,155–160 suggesting that
ER stress is occurring. We and others have reported accumu-
lation of the nonglycosylated MUC2 precursor in
UC,4,154,161,162 and biochemical evidence of ER stress and
activation of the unfolded protein response.4,92 This has led us
to propose a model whereby genetic predisposition to mis-
folding of proteins, or inappropriately responding to protein
misfolding and/or environmental ER stressors, could initiate
a chronic, or resolving and relapsing cycle of inflammation
producing an UC phenotype.4
In contrast to CD, increased intestinal permeability is
not easily demonstrated in UC.15,142 This possibly relates to
the sensitivity of the noninvasive permeability techniques,
which are best at quantifying permeability in the small bow-
el.163 There is ultrastructural evidence of inadequate tight
junctions between epithelial cells in UC which could be
attributed to the cytokines produced in UC including IL-1,
TNF-, and IL-13, which are all known to alter tight junc-
tions and intestinal permeability in cell cultures.143,164,165
However, these abnormalities in the UC colon do not appear
to be functionally significant in terms of bacterial transloca-
tion, which, in contrast to CD, is not a feature of UC.
THERAPEUTIC RESTORATION OF BARRIER
FUNCTION
Therapeutic restoration of barrier function could im-
prove pathophysiology and clinical outcomes in both CD and
UC. Unfortunately, there are few data regarding the direct
effects of current IBD therapeutics on intestinal barrier func-
tion. Immunomodulating drugs and biologicals are likely to
act in part directly or indirectly via restoration of some
aspects of barrier function and further research is required to
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dissect out the importance of these aspects of their activity.
For example, anti-TNF- antibodies could directly interfere
with the effect of this inflammatory cytokine on intestinal
permeability166 and ER stress in secretory cells,167 while
drugs that suppress T cells more generally (e.g., steroids) will
indirectly influence these pathways. A range of different
agents under study in preclinical models could affect epithe-
lial cells, for example, growth factors, trefoil peptides, anti-
oxidants, differentiation agents, iNOS inhibitors, and NF-B
inhibitors. New drugs that directly stimulate production of
constituents of the secreted barrier may not resolve advanced
lesions but have promise as agents to maintain patients in
remission without the side effects of the classical immuno-
modulating drugs. If ER stress in secretory cells proves to be
an important component of disease etiology in some patients
with IBD, then drugs that ameliorate ER stress or UPR
signaling168 could be similarly utilized to diminish the initial
triggers for inflammation. Manipulation of the luminal envi-
ronment (e.g., modifying exposure to dietary toxins and mod-
ifying the microbial microflora with anti-, pro-, or prebiotics)
may bolster the efficacy of the mucosal barrier in patients
with IBD.
SUMMARY AND KEY FUTURE RESEARCH
OBJECTIVES
In summary, emerging experimental evidence from an-
imal models suggests that altered barrier function is a poten-
tial pathway to intestinal inflammation in IBD that has re-
ceived far less attention than pathways involving underlying
immunity. Increased exploration of the complexity of barrier
function and its connections with the microbial community
and the underlying innate and adaptive immunity will en-
hance understanding of the etiology of human IBD and could
lead to more effective therapeutic strategies for these dis-
eases. Key future research objectives include:
● Identification of changes in the constituency and/or func-
tion of the microbial flora in IBD and their relationship
with the mucosal barrier.
● More detailed characterization of all elements of the mu-
cosal barrier and their interactions in health and IBD.
● Further understanding of the regulation of the mucosal
barrier by epithelial cells and underlying elements of innate
and adaptive immunity.
● Development of animal model systems encompassing both
biologically relevant genetic predisposition and appropriate
environmental challenges affecting the mucosal barrier.
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